Arbor Biotechnologies, Inc.
NEWS
Allogene Therapeutics and Arbor Biotechnologies will use their allogeneic CAR T and next-generation gene-editing platforms to develop novel off-the-shelf CAR-T therapies for autoimmune diseases.
Vertex and Arbor Biotechnologies extend partnership in precision gene editing.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here’s who snagged funding this week.
Arbor announced an oversubscribed Series B raise totaling $215 million, a significant increase from their initial $15.6 milllion Series A round to test for liver and CNS diseases.
With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years.
Biodiscovery company joins MIT accelerator for high-potential startups
With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.
Arbor Biotechnologies came out of stealth mode yesterday with a $15.6 million Series A financing round.
JOBS
IN THE PRESS